AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10919932 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (control)
Number of subjects: 36
Study 9026626 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical effort (occupational and non-occupational)
Number of subjects: 372
Study 9026626 — intervention group
Group type: COMPARATOR
Intervention: Controls (no specific intervention mentioned)
Number of subjects: 372
Study 1364197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam (n = 7)
Number of subjects: 15
Study 1364197 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg/kg vecuronium (n = 8)
Number of subjects: 15
Study 3840276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 55
Study 3840276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 55
Study 31898510 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet‐delivered behavioural intervention (BIP TIC)
Number of subjects: 0
Study 31898510 — intervention group
Group type: COMPARATOR
Intervention: Internet‐delivered education programme
Number of subjects: 0
Study 31185129 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 38
Study 31185129 — intervention group
Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 38
Study 28625628 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT)
Number of subjects: 260
Study 28625628 — intervention group
Group type: COMPARATOR
Intervention: No thoracic radiotherapy (no TRT)
Number of subjects: 260
Study 28625628 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of liver metastases
Number of subjects: 260
Study 28625628 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of bone metastases
Number of subjects: 260
Study 25837164 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze procedure
Number of subjects: 12
Study 25837164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 25837164 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze procedure with LAA preservation
Number of subjects: 12
Study 25837164 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze procedure with LAA resection
Number of subjects: 12
Study 23130748 — intervention group
Group type: EXPERIMENTAL
Intervention: T+PDE5i
Number of subjects: 56
Study 23130748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21574710 — intervention group
Group type: EXPERIMENTAL
Intervention: theoretically tailored print-based PA promotion intervention
Number of subjects: 248
Study 21574710 — intervention group
Group type: EXPERIMENTAL
Intervention: enhanced tailoring addressing 5 additional SCT constructs
Number of subjects: 248
Study 19211468 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination programs (nurses providing patient education and monitoring, mostly via telephone, with an average of two contacts per month)
Number of subjects: 18309
Study 19211468 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination programs
Number of subjects: 18309
Study 19211468 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 18309
Study 16533098 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (23-session intervention)
Number of subjects: 208
Study 12974184 — intervention group
Group type: EXPERIMENTAL
Intervention: saccharosum + sennosid-B solution
Number of subjects: 157
Study 12974184 — intervention group
Group type: COMPARATOR
Intervention: Na-picosulphate
Number of subjects: 157
Study 11094009 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic low-frequency jet ventilation (15 breaths/min)
Number of subjects: 37
Study 11094009 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic combined-frequency jet ventilation (600 and 15 breaths/min)
Number of subjects: 37
Study 11094009 — intervention group
Group type: COMPARATOR
Intervention: Supraglottic combined-frequency jet ventilation
Number of subjects: 37
Study 9353611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoset (quick-release bromocriptine)
Number of subjects: 0
Study 1288892 — intervention group
Group type: EXPERIMENTAL
Intervention: Essentiale forte
Number of subjects: 85
Study 1288892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 3905529 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy without drainage
Number of subjects: 190
Study 3905529 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without any stomach disease
Number of subjects: 190
Study 31773541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Number of subjects: 25
Study 31773541 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 25
Study 28301197 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative Regression Discontinuity Design with a Non-equivalent Comparison Group (CRD-CG)
Number of subjects: 0
Study 28301197 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Regression Discontinuity (RD)
Number of subjects: 0
Study 28301197 — intervention group
Group type: COMPARATOR
Intervention: Randomized Control Trial
Number of subjects: 0
Study 28965122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (7.20 mg ED50 for motor block)
Number of subjects: 38
Study 28965122 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine (10.05 mg ED50 for motor block)
Number of subjects: 38
Study 26313312 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free Homes (SFH) educational intervention
Number of subjects: 213
Study 26313312 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 213
Study 23208128 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutation
Number of subjects: 1935
Study 23208128 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation
Number of subjects: 1935
Study 23208128 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS/EGFR wild type
Number of subjects: 1935
Study 23208128 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1935
Study 23208128 — intervention group
Group type: COMPARATOR
Intervention: EGFR tyrosine kinase inhibitors (TKI)
Number of subjects: 1935
Study 23208128 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy among the three groups
Number of subjects: 1935
Study 22030221 — intervention group
Group type: COMPARATOR
Intervention: EPA-DHA plus ALA (n = 1009)
Number of subjects: 4116
Study 22030221 — intervention group
Group type: COMPARATOR
Intervention: EPA-DHA (n = 1007)
Number of subjects: 4116
Study 22030221 — intervention group
Group type: COMPARATOR
Intervention: ALA (n = 1022)
Number of subjects: 4116
Study 18671684 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16949943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenergetic Synchronization Technique (n = 40)
Number of subjects: 81
Study 16949943 — intervention group
Group type: COMPARATOR
Intervention: Diversified technique spinal manipulation (n = 38)
Number of subjects: 81
Study 12562319 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 141
Study 12562319 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 141
Study 10224735 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 sessions of twice-weekly exposure therapy
Number of subjects: 0
Study 10224735 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 sessions of twice-weekly exposure therapy followed by 16 sessions of behavioral family therapy (BFT)
Number of subjects: 0
Study 10224735 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 0
Study 8630312 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyloestradiol/150 micrograms desogestrel
Number of subjects: 67
Study 8630312 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyloestradiol/150 micrograms desogestrel
Number of subjects: 67
Study 8630312 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyloestradiol/75 micrograms gestodene
Number of subjects: 67
Study 8630312 — intervention group
Group type: EXPERIMENTAL
Intervention: All three groups (30 micrograms ethinyloestradiol/desogestrel, 20 micrograms ethinyloestradiol/desogestrel, 30 micrograms ethinyloestradiol/gestodene)
Number of subjects: 67
Study 8630312 — intervention group
Group type: EXPERIMENTAL
Intervention: All oral contraceptives studied
Number of subjects: 67
Study 1910103 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous regimen (20 patients)
Number of subjects: 40
Study 1910103 — intervention group
Group type: COMPARATOR
Intervention: Overlapping regimen (20 patients)
Number of subjects: 40
Study 6356972 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl concentrations below 10 micrograms/ml
Number of subjects: 0
Study 6356972 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl with 1:200 000 adrenaline
Number of subjects: 0
Study 6356972 — intervention group
Group type: EXPERIMENTAL
Intervention: More dilute solutions of epidural fentanyl
Number of subjects: 0
Study 6356972 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl with adrenaline
Number of subjects: 0
Study 6356972 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl concentrations
Number of subjects: 0
Study 27930447 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and caffeine (CHO-C) (40 g·h + 3 mg·kg)
Number of subjects: 8
Study 27930447 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO; 40 g·h)
Number of subjects: 8
Study 29938739 — intervention group
Group type: EXPERIMENTAL
Intervention: New ProTaper Next (PTN) instruments
Number of subjects: 25
Study 29938739 — intervention group
Group type: COMPARATOR
Intervention: Used ProTaper Next (PTN) instruments
Number of subjects: 25
Study 29938739 — intervention group
Group type: EXPERIMENTAL
Intervention: New Horizen (HZ) instruments
Number of subjects: 25
Study 29938739 — intervention group
Group type: COMPARATOR
Intervention: Used Horizen (HZ) instruments
Number of subjects: 25
Study 26517621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy- group (continued endoscopic ligation)
Number of subjects: 96
Study 26517621 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy+ group (combined ligation and sclerotherapy with lauromacrogol)
Number of subjects: 96
Study 26517621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 24738883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free fixed combination (FC) of tafluprost 0.0015%/timolol 0.5%
Number of subjects: 400
Study 24738883 — intervention group
Group type: COMPARATOR
Intervention: Non-fixed combination (NFC) of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 400
Study 24738883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FC and NFC)
Number of subjects: 400
Study 22569139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored-print intervention group (3 tailored newsletters over 3 months)
Number of subjects: 0
Study 22569139 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted-print intervention group (physical activity guidebook)
Number of subjects: 0
Study 22569139 — intervention group
Group type: COMPARATOR
Intervention: Standard recommendation control group (brochure detailing physical activity guidelines)
Number of subjects: 0
Study 22569139 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 19691873 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 21
Study 19691873 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study 19691873 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (8 weeks)
Number of subjects: 21
Study 17346247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill
Number of subjects: 0
Study 17346247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15791418 — intervention group
Group type: EXPERIMENTAL
Intervention: NON‐OCC (normal muscle blood flow)
Number of subjects: 22
Study 15791418 — intervention group
Group type: EXPERIMENTAL
Intervention: OCC (occluded muscle blood flow)
Number of subjects: 22
Study 15791418 — intervention group
Group type: EXPERIMENTAL
Intervention: NON‐OCC and OCC (both conditions)
Number of subjects: 22
Study 12149201 — intervention group
Group type: EXPERIMENTAL
Intervention: COL3A1‐4 carriers
Number of subjects: 1857
Study 12149201 — intervention group
Group type: EXPERIMENTAL
Intervention: COL3A1‐4
Number of subjects: 1857
Study 12149201 — intervention group
Group type: EXPERIMENTAL
Intervention: COL3A1‐3
Number of subjects: 1857
Study 12149201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1857
Study 10519471 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontemplation stage
Number of subjects: 0
Study 10519471 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation stage
Number of subjects: 0
Study 10519471 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation stage
Number of subjects: 0
Study 10519471 — intervention group
Group type: EXPERIMENTAL
Intervention: Action stage
Number of subjects: 0
Study 8771145 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic histopathology reports reviewed by a single pathologist against a checklist
Number of subjects: 1000
Study 1960551 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2A 20 x 10(6) U/m2 intramuscularly three times a week
Number of subjects: 176
Study 1960551 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha 2A 20 x 10(6) U/m2 intramuscularly three times a week with ASA 600 mg orally four times daily
Number of subjects: 176
Study 7014349 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucagon infusion (24 U regular insulin and 2.4 mg glucagon over 12 h daily for 3 weeks)
Number of subjects: 50
Study 7014349 — intervention group
Group type: COMPARATOR
Intervention: Dextrose solution (200 ml over the same time period)
Number of subjects: 50
Study 31500494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC) at 220 mmHg
Number of subjects: 20
Study 31500494 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment at 20 mmHg
Number of subjects: 20
Study 28576350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex Oromucosal Spray (active group, n=15)
Number of subjects: 30
Study 28576350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n=15)
Number of subjects: 30
Study 25538173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, folinic acid 200 mg/m2, 5-fluorouracil 3200 mg/m2 every 2 weeks)
Number of subjects: 80
Study 25538173 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus mFOLFOX-6 (oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus then 2400 mg/m2 46-h infusion every 2 weeks)
Number of subjects: 80
Study 23667876 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotector Cortexin added to standard drug therapy
Number of subjects: 0
Study 21514084 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 3687
Study 21514084 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3687
Study 19139662 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP)
Number of subjects: 56
Study 19139662 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA)
Number of subjects: 56
Study 17505806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 126
Study 17505806 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (tizanidine, fluoxetine, vinpocetin, and manual acupressure)
Number of subjects: 126
Study 12772723 — intervention group
Group type: EXPERIMENTAL
Intervention: New hyper-oxygen transmissible lenses (daily and extended wear)
Number of subjects: 0
Study 12772723 — intervention group
Group type: COMPARATOR
Intervention: Conventional lens use
Number of subjects: 0
Study 12772723 — intervention group
Group type: EXPERIMENTAL
Intervention: New hyper-oxygen transmissible lenses
Number of subjects: 0
Study 10761262 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal androgen deprivation prior to and during definitive radiation therapy
Number of subjects: 60
Study 10761262 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical audits
Number of subjects: 60
Study 8729674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr-PI allergen stimulation in PBMC of atopic patients
Number of subjects: 0
Study 8729674 — intervention group
Group type: COMPARATOR
Intervention: Cr-PI allergen stimulation in PBMC of normal controls
Number of subjects: 0
Study 8729674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr-PI allergen stimulation in T-cell cultures of atopic patients
Number of subjects: 0
Study 8729674 — intervention group
Group type: COMPARATOR
Intervention: Cr-PI allergen stimulation in T-cell cultures of normal controls
Number of subjects: 0
Study 1383434 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 238
Study 1383434 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and ABVD
Number of subjects: 238
Study 1383434 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy RT (radiation therapy) after good response to chemotherapy
Number of subjects: 238
Study 1383434 — intervention group
Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 238
Study 3904506 — intervention group
Group type: EXPERIMENTAL
Intervention: Near beer (0% alcohol), n = 11
Number of subjects: 85
Study 3904506 — intervention group
Group type: EXPERIMENTAL
Intervention: Near beer (0% alcohol), n = 8
Number of subjects: 85
Study 3904506 — intervention group
Group type: COMPARATOR
Intervention: Soft drink, n = 10
Number of subjects: 85
Study 3315765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal human insulin 100 U/ml with sodium glycocholate 4 % w/v, administered as a spray solution (0.5 U/Kg b.w.)
Number of subjects: 0
Study 3315765 — intervention group
Group type: COMPARATOR
Intervention: Intranasal regular porcine and human insulin 40 U/ml with sodium glycocholate 1 % w/v, administered in drops (0.9 U/Kg b.w.)
Number of subjects: 0
Study 3315765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glycocholate 4 % w/v
Number of subjects: 0
Study 29243164 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for Cancer Patients (EXCAP©®) - a standardized, individualized, moderate‐intensity, home‐based, six‐week progressive walking and resistance exercise program
Number of subjects: 355
Study 29243164 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 355
Study 28882167 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Quality Assurance (DQA) protocol implemented through the Data Quality Monitoring and Improvement System (DQMIS)
Number of subjects: 6300
Study 28882167 — intervention group
Group type: EXPERIMENTAL
Intervention: DQMIS components including monitoring, evaluation, training, and electronic data collection
Number of subjects: 6300
Study 26333512 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse wheat porridge (2‐mm particles)
Number of subjects: 9
Study 23135419 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week cognitive behavioral program
Number of subjects: 125
Study 23135419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 125
Study 20353621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) with Motivational Interviewing (MI) and Thought Mapping (TM)
Number of subjects: 93
Study 20353621 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Number of subjects: 93
Study 18758964 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 251
Study 17002918 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)‐3beta‐glucoside
Number of subjects: 100
Study 17002918 — intervention group
Group type: COMPARATOR
Intervention: E(2)
Number of subjects: 100
Study 14618093 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 12
Study 14618093 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 12
Study 10868622 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific CD8+ CTL response in liver transplant patients
Number of subjects: 25
Study 10868622 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific CD8+ CTL response in liver transplant patients without symptomatic CMV infection
Number of subjects: 25
Study 10868622 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy in CMV seronegative recipients
Number of subjects: 25
Study 10868622 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic CMV seronegative patients
Number of subjects: 25
Study 8899385 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational exercise more than 1.5 hours per week in the 2 years before diagnosis or referent date
Number of subjects: 1029
Study 8899385 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 1029
Study 8899385 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 1029
Study 8899385 — intervention group
Group type: COMPARATOR
Intervention: Any intensity exercise at ages 12-21 years
Number of subjects: 1029
Study 1442491 — intervention group
Group type: EXPERIMENTAL
Intervention: amiodarone plus xamoterol (200 mg two times daily)
Number of subjects: 20
Study 1442491 — intervention group
Group type: EXPERIMENTAL
Intervention: amiodarone plus metoprolol (50 mg two times daily)
Number of subjects: 20
Study 1442491 — intervention group
Group type: COMPARATOR
Intervention: amiodarone alone
Number of subjects: 20
Study 1442491 — intervention group
Group type: EXPERIMENTAL
Intervention: amiodarone plus xamoterol
Number of subjects: 20
Study 1442491 — intervention group
Group type: EXPERIMENTAL
Intervention: amiodarone plus beta-blockers (metoprolol or xamoterol)
Number of subjects: 20
Study 2857633 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (0.5 g t.i.d.)
Number of subjects: 60
Study 2857633 — intervention group
Group type: COMPARATOR
Intervention: salazosulfapyridine (1.0 g t.i.d.)
Number of subjects: 60